Navigation Links
Drug-embedded microparticles bolster heart function in animal studies
Date:10/19/2008

Researchers at Emory University and Georgia Institute of Technology have developed tiny polymer beads that can slowly release anti-inflammatory drugs and break down into non-toxic components.

When injected into rats' hearts after a simulated heart attack, the drug-embedded "microparticles" reduce inflammation and scarring, the researchers found. Injecting the particles could cut the area of scar tissue formed after the heart attack in half and boost the ability of the heart to pump blood by 10 percent weeks later.

The results are published online this week and are scheduled for publication in the Oct/Nov issue of Nature Materials.

Doctors believe that certain anti-inflammatory drugs, if delivered directly into the heart after a heart attack, could prevent permanent damage and reduce the probability of heart failure later in life.

Fulfilling this idea -- getting drugs to the right place at the right time -- is more challenging than simply swallowing an aspirin, says senior author Michael Davis, PhD, assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

"If you look at previous studies to see what it would take to get enough of these drugs into the heart, they did things like direct injections twice a day," he says. "And there are clear toxicity issues if the whole body is exposed to the drug."

As an alternative, Davis and graduate student Jay Sy, the first author of the paper, turned to microscopic particles made of a material called polyketals, developed by co-author Niren Murthy, PhD, assistant professor of biomedical engineering.

The microparticles break down over a few weeks in the body, releasing the experimental drug SB239063. This drug inhibits an enzyme, MAP kinase, which is important during the damaging inflammation that occurs after a heart attack.

Davis says the drug gradually leaches out of the polyketal p
'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Broad Institute awarded major grant to bolster epigenomics research
2. Argonne-University of Chicago joint venture bolsters genomic sequencing capabilities
3. Student study bolsters case for adding a rare sunflower to the endangered species list
4. Student study bolsters case for adding a rare sunflower to the endangered species list
5. Repair in the developing heart
6. Embryonic heart exhibits impressive regenerative capacity
7. Study provides insight on a common heart rhythm disorder
8. LIAI launches new division to look at novel approaches to heart disease and inflammation
9. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
10. Researchers study how pistachios may improve heart health
11. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... researchers hope to take a healthy salad up a ... of breast cancer in leafy greens. , "In the ... either by eating the salad or making a pill ... of biomedical engineering at Case Western Reserve School of ... G. Komen breast cancer organization is funding the research ...
(Date:9/30/2014)... Evidence of the environmental effects of moorland burning is ... the subject, with the aim of relieving tensions on ... , The EMBER (Effects of Moorland Burning on the ... burning on moorland, which is practised predominantly to support ... impacts on peat hydrology, peat chemistry and physical properties, ...
(Date:9/30/2014)... WASHINGTON, D.C., September 30, 2014--Sea monkeys have captured the ... of their easily observable life cycle -- sold as ... and mate given little more than a tank of ... a shorter-term pattern: Like other zooplankton, brine shrimp vertically ... conditions, coming closer to the surface at night and ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2
... available in German . ... animal behaviour that is subject to annual rhythms is controlled by ... time, in many cases it is still unclear how far genes ... also applied to the common buzzard and its migration from parental ...
... , This news release is available in ... are bad at getting a grip on collective risks. Climate change ... so far not led to specific measures. The reason for this ... than to investing in future quality of life. Therefore, ...
... physicians and biologists alike - even though it is well-established ... stages, immobility can all be traced back to the death ... neuron. The underlying cause of this cellular death is a ... external factors, most of the details of which are well-known. ...
Cached Biology News:The molecular clock of the common buzzard 2People don't put a high value on climate protection 2People don't put a high value on climate protection 3PD map: Putting together the pieces of the Parkinson's puzzle 2PD map: Putting together the pieces of the Parkinson's puzzle 3
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... Industry leaders from retail pharmacies to ... theme, ,Commercial Opportunities in the Era of Reform, from ... Elsevier , a world-leading provider of scientific, technical and ... of some of the industry,s most prominent healthcare leaders ... in the future. The Elsevier Healthcare and ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... 5 , - Data Presented ... York , ThromboGenics NV (Euronext Brussels: ... innovative medicines for eye,disease, vascular disease and cancer, today announces ... the treatment of,Diabetic Macular Edema (MIVI II DME). The data ...
... , LA JOLLA, Calif., Oct. 5 Transdel Pharmaceuticals, Inc. ... a conference call and audio webcast on Tuesday, October 6, ... of its Phase 3 clinical study for Ketotransdel®, a topical ... A press release will be issued on Tuesday, October 6, ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
Cached Biology Technology:ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 4Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 2Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
Request Info...
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Request Info...
Biology Products: